articleTop 1% cited

Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease

Archives of Neurology · 2003 · Vol. 60(12) · pp. 1685–1685

Craig Ritchie✉Ashley I. Bush(University of Melbourne)Andrew Mackinnon(Monash Health)Steve Macfarlane(University of Melbourne)Maree Mastwyk(University of Melbourne)Lachlan MacGregor(University of Melbourne)Lyn Kiers(University of Melbourne)Robert A. Cherny(University of Melbourne)Qiao‐Xin Li(University of Melbourne)Amanda Tammer(University of Melbourne)Darryl Carrington(University of Melbourne)Christine Mavros(University of Melbourne)Irene Volitakis(University of Melbourne)Michel Xilinas(University of Gothenburg)David Ames(University of Melbourne)Stephen N. Davis(University of Melbourne)Konrad Beyreuther(Heidelberg University)Rudolph E. Tanzi(Massachusetts General Hospital)Colin L. Masters(University of Melbourne)

View via DOI Publisher page

Abstract

Subject to the usual caveats inherent in studies with small sample size, this pilot phase 2 study supports further investigation of this novel treatment strategy using a metal-protein-attenuating compound.

Alzheimer's disease research and treatments Trace Elements in Health Computational Drug Discovery MethodsClioquinolAlzheimer's diseasePlaceboPharmacologyToxicityMedicineInternal medicineDrugDiseasePathology

MeSH terms

AgedAged, 80 and overAlzheimer DiseaseChelating AgentsCognitionCopperDouble-Blind MethodFemaleHumansClioquinolMaleMiddle AgedPeptide FragmentsPilot ProjectsSeverity of Illness Index